After maturation, MSTN is expressed in various tissues,[12,20,21] with the highest levels in skeletal muscle and lower levels in visceral and subcutaneous fat,[21] as well as cardiac muscle.[20] MSTN has also been reported to negatively regulate adipocyte differentiation and lipid accumulation by suppressing the expression of key transcription factors such as peroxisome proliferator-activated receptor (PPAR-) and CCAAT/enhancer binding protein-.[22] However, Mstn / mice exhibit significantly reduced fat accumulation under normal aging conditions despite a lower metabolic rate, [23] whereas a genetically obese mouse model shows elevated MSTN mRNA levels compared to wild-type mice, suggesting a positive correlation between MSTN expression and fat mass.[21] These findings have paved the way for MSTN to become a therapeutic target not only for muscle atrophy, but also for diabetes and obesity

We believe in uplifting our community through personalized, science-backed wellnesswhere every client is supported, celebrated, and guided with compassion
When retatrutide becomes available, the candidate criteria will likely be similar to other weight loss medications
doi:10.1053/j.jrn.2025.02.001